Svar 公司專(zhuān)注于大分子配體結(jié)合分析和基于細(xì)胞的分析研究，在抗體和多肽藥物、基因和載體的治療方面豐富有經(jīng)驗(yàn)，涉及領(lǐng)域包括腫瘤學(xué)、自身免疫、內(nèi)分泌疾病和神經(jīng)學(xué)相關(guān)研究領(lǐng)域，同時(shí)提供相關(guān)領(lǐng)域疾病的藥物和解決方案，提供完整的CRO 產(chǎn)品。
北京博蕾德生物是Svar 公司授權(quán)的中國(guó)區(qū)總代理，更多Svar 公司產(chǎn)品信息，請(qǐng)咨詢北京博蕾德生物科技有限公司。
以下是Svar 公司授權(quán)博蕾德生物為中國(guó)區(qū)總代理授權(quán)書(shū)。

特色產(chǎn)品推薦：
**補(bǔ)體檢測(cè)試劑盒
1）藥物開(kāi)發(fā)-補(bǔ)體靶向治療
研究表明,炎性疾病的發(fā)生、發(fā)展同補(bǔ)體的活化有關(guān)。因此,如何干擾和抑制補(bǔ)體活化產(chǎn)生的有害作用,成為藥理學(xué)研究的焦點(diǎn)之一，Euro Diagnostica試劑盒用于評(píng)估補(bǔ)體靶向治療效果（參考文獻(xiàn)4-8）。
2）臨床研究-補(bǔ)體功能/活性監(jiān)測(cè)
補(bǔ)體功能的評(píng)估在補(bǔ)體相關(guān)疾病的發(fā)生和治療中具有重要意義。文獻(xiàn)5-9 用Euro Diagnostica試劑盒監(jiān)測(cè)補(bǔ)體疾病治療中補(bǔ)體水平。
3）補(bǔ)體脫靶反應(yīng)
在某些情況下，補(bǔ)體激活可引起嚴(yán)重反應(yīng)，比如候選藥物的脫靶反應(yīng)，抗體依賴的補(bǔ)體激活，移植排斥反應(yīng)。（（參考文獻(xiàn)12-13）。）
訂購(gòu)信息

貨號(hào)	產(chǎn)品名稱	規(guī)格
COMPL300	Complement system Screen WIESLAB®	96T
COMPLCP310	Complement system Classical Pathway WIESLAB®	96T
COMPLMP320	Complement system MBL pathway WIESLAB®	96T
COMPLAP330	Complement system Alternative Pathway WIESLAB®	96T

應(yīng)用文獻(xiàn)：
1.Ricklin D and Lambris JD.Complement in Immune and Inflammatory Disorders:Therapeutic Interventions. J Immunol 2013; 190: 3839-3847
2. Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of
the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005; 296: 187–198
3. Salvesen B and Mollnes TE. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Mol Imm 2009;6:1620-1625
4.Hill A et al. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results. Abstract 2413 ;58th ASH Annual Meeting 2015
5. Jore MM et al. Structural basis for therapeutic inhibition of complement C5. Nature Structural & Molecular Biology 2016: doi:10.1038/nsmb.3196
6. Würzner R et al. Assessment of complement activity by ELISA. Abstract #41 16th Biennial Meeting of the European Society for Immunodeficiencies, ESID 2014
7. Kocsis A. Selective Inhibition of the Lectin Pathway of Complement with
Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine
Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway
Activation. J of Immunol 2010;185: 4169–4178
8. Kadam A P and Sahu A Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. J of Immunol 2010;184: 7116-24
9. Volokhina E B et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015; 160: 237–43
10. Heinen S et al. Monitoring and modeling treatment of atypical hemolytic uremic
syndrome. Molecular Immunology 2013; 54:84– 88
11. Hallenstensen RF et al. Eculizumab treatment during pregnancy does not affect the
complement system activity of the newborn. Immunobiology 2015; 220:452–459
12. Castellano G et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion- Induced Renal Damage. Am J Pathol 2010; 176:1648–1659
13. Brennan FR et al. Safety and immunotoxicity assessment of immunomodulatory
monoclonal antibodies. mAbs 2010; 2:3, 233-255
14. Mitsuru Sugimoto,etal.Possible participation of IgG4 in the activation of complement in IgG4-related disease with  hypocomplementemia.Modern Rheumatology,Volume 26, 2016 - Issue 2
15．Y. Palarasah,etal.Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system.Clincal&Experimental Immunology,Volume164, Issue3,June 2011,Pages 388-395.